- Home
- QURE vs TBPH Comparison
QURE vs TBPH Comparison
Compare QURE & TBPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- QURE
- TBPH
- Stock Information
- Founded
- QURE 1998
- TBPH 2013
- Country
- QURE Netherlands
- TBPH United States
- Employees
- QURE N/A
- TBPH N/A
- Industry
- QURE Biotechnology: Pharmaceutical Preparations
- TBPH Biotechnology: Pharmaceutical Preparations
- Sector
- QURE Health Care
- TBPH Health Care
- Exchange
- QURE Nasdaq
- TBPH Nasdaq
- Market Cap
- QURE 432.6M
- TBPH 394.4M
- IPO Year
- QURE 2007
- TBPH N/A
- Fundamental
- Price
- QURE $6.65
- TBPH $8.81
- Analyst Decision
- QURE Buy
- TBPH Buy
- Analyst Count
- QURE 6
- TBPH 4
- Target Price
- QURE $19.50
- TBPH $13.75
- AVG Volume (30 Days)
- QURE 846.7K
- TBPH 172.5K
- Earning Date
- QURE 11-05-2024
- TBPH 11-05-2024
- Dividend Yield
- QURE N/A
- TBPH N/A
- EPS Growth
- QURE N/A
- TBPH N/A
- EPS
- QURE N/A
- TBPH N/A
- Revenue
- QURE $27,707,000.00
- TBPH $62,017,000.00
- Revenue This Year
- QURE $187.60
- TBPH $6.93
- Revenue Next Year
- QURE $51.90
- TBPH $45.31
- P/E Ratio
- QURE N/A
- TBPH N/A
- Revenue Growth
- QURE N/A
- TBPH 20.97
- 52 Week Low
- QURE $3.73
- TBPH $7.44
- 52 Week High
- QURE $11.35
- TBPH $11.71
- Technical
- Relative Strength Index (RSI)
- QURE 63.87
- TBPH 57.03
- Support Level
- QURE $6.01
- TBPH $8.51
- Resistance Level
- QURE $6.55
- TBPH $8.82
- Average True Range (ATR)
- QURE 0.54
- TBPH 0.23
- MACD
- QURE 0.18
- TBPH 0.06
- Stochastic Oscillator
- QURE 91.67
- TBPH 70.74
About QURE uniQure N.V.
uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases.
About TBPH Theravance Biopharma Inc.
Theravance Biopharma Inc is a diversified biopharmaceutical company focused on the discovery, development, and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small-molecule drugs designed to better meet patient needs. Its research is focused on the areas of inflammation and immunology. The firm applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. The company develops lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).